Azenta, Inc. (AZTA) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

14/25

Growth 3 Margin 1 Expansion 4 Platform 2 Financial 4

latest quarter score

Earnings Reports

14
Azenta (AZTA) Q3 2026: 9% Organic Growth Driven by Biorepository and CNI Momentum
August 05, 2026
12
Azenta (AZTA) Q1 2026: Gross Margin Falls 360bps as Turnaround Leans on Second-Half Ramp
June 15, 2026
13
Azenta (AZTA) Q2 2026: Multiomics Down Mid-Single Digits, Forcing 1-Year Long-Range Plan Delay
May 06, 2026
16
Azenta (AZTA) Q4 2025: MultiOmics Hits Record $73M, Margin Expansion Signals Operational Reset
November 21, 2025
16
Azenta (AZTA) Q3 2025: SMS Margins Surge 760bps as Mix and Execution Offset Flat Revenue
August 05, 2025
22
Azenta (AZTA) Q2 2025: 400bps Margin Expansion Signals Early Payoff from Lean Overhaul
July 06, 2025
Azenta (AZTA) Q4 2024: Core Margin Expands 300bps as Portfolio Refocus Accelerates
November 12, 2024
Azenta (AZTA) Q3 2024: EBITDA Margin Expands 440bps as Automation and Cost Actions Accelerate
August 06, 2024
Azenta (AZTA) Q2 2024: B Medical Revenue Cut by $30M as Focus Shifts to Vaccine Cold Chain Margin
May 08, 2024
Azenta (AZTA) Q1 2024: SMS Ex-CNI Grows 9% as Automation and Repository Demand Outpace Market
February 07, 2024
19
Azenta (AZTA) Q4 2023: $500M Buyback, B Medical Pipeline Upside, Margin Expansion in Focus
November 13, 2023
Azenta (AZTA) Q3 2023: Automated Store Revenue Jumps 15%, Underscoring Workflow Automation Tailwind
August 08, 2023
Azenta (AZTA) Q2 2023: B Medical Revenue Drops $27M, Forcing Guidance Reset and Cost Realignment
May 09, 2023

Browse all companies